Daily Sepsis Research Analysis
Three impactful studies advance sepsis-related care across treatment, mechanisms, and prevention. A meta-analysis of RCTs shows that 7 days of antibiotics are comparable to 14 days for bacteremia outcomes, supporting stewardship. Mechanistic work identifies an SP1/PHB1 axis driving macrophage dysfunction in sepsis-induced lung injury, and a lipid-coated nanoparticle toxoid platform achieves cross-species protection against MRSA and Pseudomonas infections.
Summary
Three impactful studies advance sepsis-related care across treatment, mechanisms, and prevention. A meta-analysis of RCTs shows that 7 days of antibiotics are comparable to 14 days for bacteremia outcomes, supporting stewardship. Mechanistic work identifies an SP1/PHB1 axis driving macrophage dysfunction in sepsis-induced lung injury, and a lipid-coated nanoparticle toxoid platform achieves cross-species protection against MRSA and Pseudomonas infections.
Research Themes
- Antibiotic stewardship and optimal treatment duration in bacteremia
- Macrophage polarization and endothelial–immune crosstalk in sepsis-associated lung injury
- Antivirulence toxoid vaccine platforms for preventing severe bacterial infections
Selected Articles
1. Antimicrobial treatment for 7 versus 14 days in patients with bacteremia: a meta-analysis of randomized controlled trials.
Across four RCTs (n=4,790), 7-day antibiotic therapy for bacteremia yielded similar 90-day mortality, recurrence, and length of stay compared with 14-day therapy. Safety outcomes, including C. difficile infection and resistance emergence, were also comparable, supporting shorter courses in appropriate patients.
Impact: This RCT-based meta-analysis provides high-level evidence that shorter antibiotic courses are non-inferior in bacteremia, informing stewardship and potentially reducing adverse events and resistance.
Clinical Implications: Clinicians can consider 7-day antibiotic regimens for stable bacteremia patients consistent with trial populations, with attention to source control and host factors when individualizing therapy.
Key Findings
- Four RCTs (n=4,790) comparing 7 vs 14 days of antibiotics in bacteremia
- 90-day mortality: RR 0.93 (95% CI 0.81–1.07), p=0.30
- Recurrence of bacteremia similar: RR 1.14 (95% CI 0.80–1.63), p=0.47
- Length of stay not different: mean difference −0.18 days (95% CI −1.03 to 0.67), p=0.69
- Safety outcomes (including C. difficile, AKI, resistance) comparable between groups
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials
- Large aggregated sample size with mortality, recurrence, and safety endpoints
- Use of prediction intervals to reflect between-trial heterogeneity
Limitations
- Only four RCTs included; heterogeneity in pathogens, sources, and inclusion criteria
- Limited subgroup data for high-risk populations (e.g., immunocompromised, MDR organisms)
Future Directions: Prospective RCTs stratified by pathogen, source, and host risk, including immunocompromised patients, to refine duration recommendations.
PURPOSE: The optimal duration of antibiotic treatment in patients with bacteremia is a matter of ongoing debate. METHODS: We conducted a meta-analysis of randomized controlled trials that compared 7 days with 14 days of antimicrobial treatment in adults with bacteremia. The systematic search included trials published until December 2024. Efficacy outcomes included 90-day all-cause mortality, recurrence of bacteremia and mean length of hospital stay. Safety outcomes included the total number of adverse events, Clostridioides difficile infections, diarrhea, acute kidney injury, rash or emergence of antibiotic resistance. RESULTS: The final analysis included four randomized controlled trials with a total of 4790 participants. Death by day 90 occurred in 321 (13.3%) of 2406 patients receiving antibiotic treatment for 7 days and 342 (14.3%) of 2384 patients receiving antibiotic treatment for 14 days (RR 0.93 [95% CI, 0.81 to 1.07)]; p = 0.30; prediction interval 0.74 to 1.17). The mean hospital stay did not differ significantly (mean difference - 0.18 days [95% CI, -1.03 to 0.67]; p = 0.69; prediction interval - 2.57 to 2.22). Recurrence of bacteremia was similar between antibiotic treatment for 7 days (64 [2.7%] of 2406) and antibiotic treatment for 14 days (56 [2.3%] of 2384) (RR 1.14 [95% CI, 0.80 to 1.63)]; p = 0.47; prediction interval 0.64 to 2.03). Safety outcomes, including the total number of adverse events, Clostridioides difficile infections, diarrhea, acute kidney injury, rash, and antibiotic resistance, were similar between groups. CONCLUSIONS: This meta-analysis suggests that 7-day and 14-day antimicrobial treatment is associated with a similar efficacy and safety profile in patients with bacteremia.
2. Lipid-coated nanoparticles enhance the delivery of bacterial virulence factors as a potent toxoid vaccine platform against bacterial infections.
A PS-liposome–coated, CpG-core nanoparticle (PSV-CNP) efficiently absorbs bacterial virulence factors and elicits robust, durable immunity. It protected mice and Bama pigs against MRSA, clinical S. aureus isolates, and Pseudomonas infections, including under immunosuppression, establishing a broadly applicable antivirulence toxoid platform.
Impact: Introduces a versatile antivirulence vaccine platform with efficacy across species and pathogens, addressing a critical unmet need in preventing severe bacterial infections that can lead to sepsis.
Clinical Implications: While preclinical, this platform could be developed for high-risk populations (e.g., surgical, oncology, ICU) to reduce invasive infections and downstream sepsis once safety and immunogenicity are demonstrated in humans.
Key Findings
- PSV-CNP consists of a CpG-loaded polymeric core coated with PS liposomes enriched with bacterial virulence factors
- Induced robust humoral immunity and long-lasting protection in mice against MRSA and clinical S. aureus isolates, including under immunosuppression
- Elicited strong immune responses in Bama pigs and prevented MRSA/CI-SA invasion
- PS-liposomes absorbed virulence factors from Pseudomonas aeruginosa, conferring protection against PA infections
Methodological Strengths
- Demonstrated efficacy in two species (mice and pigs), enhancing translational relevance
- Protection shown under immunosuppression, addressing a clinically relevant context
- Broad pathogen coverage (MRSA, clinical S. aureus, Pseudomonas aeruginosa)
Limitations
- Preclinical data; human safety, durability, and breadth of protection remain untested
- Antigen composition and manufacturing scalability require optimization
Future Directions: Advance to GMP production and phase I trials, define immunological correlates, and evaluate protection against diverse clinical isolates and polymicrobial exposures.
Antivirulence vaccination represents a promising strategy for infection prevention, but achieving both safety and efficacy in toxoid vaccine preparation remains a challenge. Cell membrane-based nanotoxoids offer a safe delivery platform for bacterial virulence factors in antivirulence vaccination, but limited absorption capacity hampers their efficacy. Here, we develop a lipid-based toxoid vaccine platform, PSV-CNP, comprising a CpG-loaded polymeric core coated with phosphatidylcholine/sphingomyelin (PS) liposomes enriched with bacterial virulence factors. By enhancing virulence factor absorption, PSV-CNP elicits robust humoral immunity. In mice, it provides long-lasting protection against methicillin-resistant Staphylococcus aureus (MRSA) and clinically isolated S. aureus (CI-SA), even under immunosuppression. In Bama pigs, PSV-CNP induces strong immune responses and prevents MRSA and CI-SA invasion. Furthermore, PS-liposomes efficiently absorb virulence factors from Pseudomonas aeruginosa (PA), conferring protection against PA infections. This study establishes PS-coated nanoparticles as a broadly applicable, safe, and effective antivirulence toxoid vaccine platform.
3. Specificity protein 1 suppresses prohibitin 1 to induce macrophage M1 polarization and impair phagocytosis, exacerbating sepsis-associated acute lung injury.
In CLP-induced sepsis models, SP1 transcriptionally suppresses PHB1, driving M1 macrophage polarization and impaired phagocytosis, thereby worsening lung inflammation, fibrosis, and apoptosis. Overexpressing PHB1 reverses these effects, implicating the SP1/PHB1 axis as a therapeutic target in sepsis-associated ALI.
Impact: Reveals a previously unrecognized SP1/PHB1 regulatory axis that links macrophage polarization and phagocytic dysfunction to sepsis lung injury, providing a mechanistic basis for targeted immunomodulation.
Clinical Implications: Although preclinical, targeting SP1/PHB1 or restoring PHB1 function could modulate macrophage responses to ameliorate lung injury in sepsis; biomarkers of SP1/PHB1 activity may aid patient stratification.
Key Findings
- SP1 and PHB1 identified as key regulators in sepsis-associated ALI using CLP mouse models, scRNA-seq, HTS, and ML
- SP1 transcriptionally suppresses PHB1, promoting M1 polarization and impairing macrophage phagocytosis
- SP1 overexpression increases lung inflammation, fibrosis, and apoptosis; PHB1 overexpression reverses these effects
- Macrophage dysfunction linked to mitochondrial impairment and oxidative stress via the SP1/PHB1 axis
Methodological Strengths
- Integration of scRNA-seq, HTS, and machine learning with in vivo CLP models and in vitro validation
- Gain- and loss-of-function experiments to establish causality
- Multiple orthogonal assays (IF, ELISA, RT-qPCR, Western blot) for validation
Limitations
- Preclinical animal model; human validation of SP1/PHB1 axis and clinical biomarker utility remain to be shown
- CLP model may not capture full heterogeneity of human sepsis-associated ALI
Future Directions: Validate SP1/PHB1 signatures in human sepsis lung samples, develop small-molecule or genetic modulators, and test efficacy in diverse sepsis models.
Sepsis-related acute lung injury (ALI) is a severe and life-threatening complication characterized by excessive inflammation and immune dysfunction. Macrophages play a central role in the pathogenesis of ALI, with dysregulated polarization and impaired phagocytic function contributing to disease progression. This study investigates the role of the Specificity Protein 1 (SP1)/Prohibitin 1 (PHB1) axis in regulating macrophage polarization and function in sepsis-associated ALI. Using a cecal ligation and puncture (CLP)-induced mouse model, combined with single-cell RNA sequencing (scRNA-seq), high-throughput sequencing (HTS), and machine learning (ML) algorithms, we identified SP1 and PHB1 as key regulators of ALI. Functional assays demonstrated that SP1 transcriptionally suppresses PHB1 expression, promoting M1 macrophage polarization while impairing phagocytic function, thereby exacerbating sepsis-induced ALI. Immunofluorescence, enzyme-linked immunosorbent assay (ELISA), quantitative polymerase chain reaction (RT-qPCR), and Western blot analyses further validated these findings. In vivo and in vitro studies confirmed that overexpression of SP1 significantly increased lung inflammation, fibrosis, and apoptosis, whereas PHB1 overexpression reversed these pathological effects. The SP1/PHB1 axis was found to modulate macrophage-mediated immune responses through inflammatory cytokine secretion, mitochondrial dysfunction, and oxidative stress. These findings provide novel insights into the molecular mechanisms underlying sepsis-induced ALI and highlight the potential of targeting the SP1/PHB1 axis for therapeutic intervention. Future research should explore targeted therapies aimed at modulating macrophage polarization and improving immune homeostasis in sepsis-associated ALI.